Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | TOP1 | P11387 | 1/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31162811 | 1.00 | ACHE (0.53) | ACHECYP3A4PDE4DCYP19A1MAOB | |
| SCHEMBL16110979 | 0.81 | HTR2A (0.44) | ACHEMAOBKCNJ1KDM4EALDH1A1 | |
| SCHEMBL31119631 | 0.81 | HTR2A (0.44) | ACHEMAOBKCNJ1KDM4EALDH1A1 | |
| SCHEMBL16111006 | 0.80 | TIPARP (0.41) | CYP3A4PDE4DMAOBKCNJ1 | |
| SCHEMBL7632703 | 0.80 | PTGS2 (0.47) | ACHEPDE4DMAOBKCNJ1KDM4E | |
| SCHEMBL4110681 | 0.79 | KDM4E (0.57) | ACHECYP3A4PDE4DCYP19A1MAOB | |
| SCHEMBL6607183 | 0.77 | PDE4D (0.46) | ACHECYP3A4PDE4DCYP19A1MAOB | |
| SCHEMBL27988062 | 0.76 | ALOX5 (0.56) | CYP3A4CYP19A1MAOBLMNAALDH1A1 | |
| SCHEMBL2587484 | 0.76 | PDE4D (0.48) | ACHECYP3A4PDE4DCYP19A1MAOB | |
| SCHEMBL2591157 | 0.76 | HDAC4 (0.51) | ACHECYP3A4PDE4DMAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024197354-A1 | COMBINATION OF MICROBES FOR USE IN AGRICULTURE | New Edge Microbials Pty Ltd (AU) | 2024-10-03 | — | — | WO | disclosed |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-9790215-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790215-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790215-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9783529-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| EP-1241169-A1 | Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-09-18 | — | — | EP | disclosed |
| US-6001877-A | OF GIVEN FORMULA, WHICH ACTS AS AN ANTAGONIST OF LEUKOTRIENES; ADMINISTERING TO TREAT LEUKOTRIENE-B4 INDUCED DISEASES, SUCH AS ALLERGIES AND INFLAMMATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5795914-A | Phenylalkan(en)oic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-08-18 | — | — | US | disclosed |
| EP-0405116-B1 | Phenylalkan(en)oic acids | ONO PHARMACEUTICAL CO (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-5457122-A | Leukotriene antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-10-10 | — | — | US | disclosed |
| US-5256686-A | Antiinflammatory agent, antiallergens | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-10-26 | — | — | US | disclosed |
| US-5155104-A | Phenylalkan(en)oic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| US-5086065-A | Leukotriene antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0405116-A2 | Phenylalkan(en)oic acids | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-01-02 | — | — | EP | disclosed |
| US-3954998-A | HERBICIDES | UNION CARBIDE CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PNPO | ACHE 2909/4885CYP3A4 1000/4885PDE4D 1371/4885 |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | CFTR, SLC26A4, PNPO | ACHE 2909/4885CYP3A4 1000/4885PDE4D 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.